Navigation Links
-Ingen Technologies Registers Oxyview(R) in Taiwan-
Date:2/20/2008

YUCAIPA, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Ingen Technologies, Inc. (Pink Sheets: IGTG), a new medical device manufacturer, announced today that the Taiwan registration process for Oxyview(R) with their exclusive Asian distributor, Progressive International Holding Company Ltd., has been initiated. Progressive International Holding Company is working directly with the Taipei Economic and Cultural Representative Office in the United States for the Certificate to Foreign Government.

Progressive International Holding Company has been a strong presence in the Asian healthcare market during the past twenty years. In view of China as one of the fastest growing countries in the world and with the rising demand for healthcare products inland, Progressive International Holding Company has introduced Oxyview(R) to the Taiwan, China, Japan and Korea medical market. Not only does Progressive International Holding Company want to pursue a leading role in the diagnostic, medical device and POC markets in China, but also has a strong position in Taiwan. With a stronghold of Primus Medical (Shanghai) and Taiwan's experience, Progressive International Holding Company shall have a strong and unique position in the Asian healthcare market to sell Oxyview(R).

"Ingen Technologies is working close with Progressive International Holding Company to complete the registration process for Oxyview(R). This process is similar to the FDA and DHS compliances that Ingen and Oxyview(R) have already successfully completed last year," said Scott Sand, Chairman and CEO.

For more information please visit: http://www.wallst.net/superstocks/superstocks_profile.asp?ticker=igtg

About Ingen Technologies, Inc.

Ingen Technologies is a new medical device manufacturer that owns proprietary intellectual property for the growing respiratory market. The Oxyview(R) was recently assigned Class-I with the Food & Drug Administration. The Company has several other related products being scheduled for release during 2008 and will continue to roll-out additional medical products during the next several years. The principals and management of Ingen Technologies are committed to the success of the company and have invested more than $5 million of their own money towards R&D and the manufacturing of proprietary biotech products for the medical market. The Company owns multiple Patents and Trademarks in the United States, European Communities, Japan, and the Peoples Republic of China. The Company has had revenues since 2002 with their Secure Balance(R) products, and has recently released their new Oxyview(R) product worldwide through two of the world's largest home health care distributors in the United States, Asia and 80 other countries. Further, new markets in Asia have been recently secured with monthly deliveries of 10,000 Oxyview(R) units. The Company's respiratory product line will benefit from the $4 billion respiratory market that will grow to $6 billion by 2010. With 8-9% of Americans over 65 that have a respiratory illness and require home oxygen therapy, the world market is 10-12% and offers a growing revenue stream for the company. The elderly population in the United States will double between 2010 and 2015, increasing the number of respiratory illnesses and increasing the need for Oxyview(R) and OxyAlert(R).

For more information, visit: http://www.ingen-tech.com

Contact: Scott R. Sand, C.E.O & Chairman

Ingen Technologies, Inc. - Administrative Office

35193 Avenue "A", Suite-C

Yucaipa, California 92399

Phone: (909) 790-7180

Fax: (909) 795-6340

Email: Info@ingen-tech.com

A Member of the Better Business Bureau

A Member of the Chamber of Commerce

A Licensed Business in the City of Yucaipa

A Certified Manufacturer with FDA/DHS

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.


'/>"/>
SOURCE Ingen Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CryoCath Technologies notice of annual meeting
2. Accenx Technologies Brings Healthcare IT Solutions to HIMSS08 Interoperability Showcase
3. Global Med Technologies(R), Inc. Adds Internationally Renowned NewYork- Presbyterian Hospital to Client List
4. Greenway Medical Technologies Broadens Sales Efforts With Entrance Into Federally Qualified Health Center Marketplace
5. Global Med Technologies(R), Inc. Receives FDA 510(K) Clearance for ElDorado Donor(TM)
6. Global Med Technologies(R), Inc. Recieves FDA 510(K) Clearance for ElDorado Donor(TM)
7. China Display Technologies, Inc. to Present at Roth Conference
8. Nano Pet Products, LLC Named Exclusive Worldwide Licensee by Schoeller(R) Technologies AG for Pet Products to Develop the Most Technologically Advanced Pet Brands on the Market Today
9. ReBuilder Medical Technologies, Inc. Announces 2007 Sales Nearly Doubled Sales in 2006
10. Upcoming meeting will explore new technologies for glaucoma clinical drug trials
11. Ingen Technologies Brings Oxyview(R) to Asia Through Major Medical Distributor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: